Tom Howing In this job you get to meet a lot of remarkable people, none more so than the patients who volunteer to take part in what are giant experiments. They are courageous pioneers, willing to be among the first people to ever try a new therapy, knowing that it may not help them and, … Continue reading Saying thanks and farewell to a friend
Forty Seven Inc.
A model for success
Dr. Maria Millan, CIRM's President & CEO Funding models are rarely talked about in excited tones. It’s normally relegated to the dry tomes of academia. But in CIRM’s case, the funding model we have created is not just fundamental to our success in advancing regenerative medicine in California, it’s also proving to be a model … Continue reading A model for success
Perseverance: from theory to therapy. Our story over the last year – and a half
Some of the stars of our Annual Report It’s been a long time coming. Eighteen months to be precise. Which is a peculiarly long time for an Annual Report. The world is certainly a very different place today than when we started, and yet our core mission hasn’t changed at all, except to spring into … Continue reading Perseverance: from theory to therapy. Our story over the last year – and a half
CIRM Highlights Industrial Alliance Program (IAP)
In the addition to the innovative scientists and clinicians who conceive and develop novel experimental therapies, it takes a village to drive a promising experimental therapy through phases of clinical trials, regulatory marketing approval, and commercialization before it becomes broadly accessible to patients with unmet medical needs. In this case, the village is the broader … Continue reading CIRM Highlights Industrial Alliance Program (IAP)
Big time validation for early support
It’s not every day that a company and a concept that you helped support from the very beginning gets snapped up for $4.9 billion. But that’s what is happening with Forty Seven Inc. and their anti-cancer therapies. Gilead, another California company by the way, has announced it is buying Forty Seven Inc. for almost $5 … Continue reading Big time validation for early support
New Report Says CIRM Produces Big Economic Boost for California
An independent Economic Impact Report says the California Institute for Regenerative Medicine (CIRM) has had a major impact on California’s economy, creating tens of thousands of new jobs, generating hundreds of millions of dollars in new taxes, and producing billions of dollars in additional revenue for the state. The report, done by Dan Wei and … Continue reading New Report Says CIRM Produces Big Economic Boost for California
CIRM funded clinical trial shows promising results for patients with blood cancers
An illustration of a macrophage, a vital part of the immune system, engulfing and destroying a cancer cell. Antibody 5F9 blocks a "don't eat me" signal emitted from cancer cells. Courtesy of Forty Seven, Inc. Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are both types of blood cancers that can be difficult to treat. CIRM … Continue reading CIRM funded clinical trial shows promising results for patients with blood cancers
By the numbers – a look at how the field of Regenerative Medicine is growing
The Golden State Warriors, the current US basketball champions – and your favorite Stem Cell Agency’s neighbors in Oakland – have a slogan, “Strength in Numbers”. That could well apply to the field of Regenerative Medicine because the field is growing in numbers, growing in strength, and growing in influence. Yesterday, the Alliance for Regenerative … Continue reading By the numbers – a look at how the field of Regenerative Medicine is growing
How CIRM support helped a promising approach to type 1 diabetes get vital financial backing
The “Valley of Death” sounds like a scary place from “Lord of the Rings” or “Game of Thrones” that our heroes have to navigate to reach safety. The reality is not that different. It’s the space that young companies have to navigate from having a good idea to getting financial backing, so they can move … Continue reading How CIRM support helped a promising approach to type 1 diabetes get vital financial backing
Saying goodbye to a good friend and a stem cell pioneer: Karl Trede
Sometimes even courage and determination are not enough. Karl Trede had courage and determination in droves as he fought a 12 year battle against cancer. He recently lost that battle. But he remains an inspiration for all who knew him. I got to know Karl for our 2016 Annual Report. Karl had been diagnosed with … Continue reading Saying goodbye to a good friend and a stem cell pioneer: Karl Trede
The Stem Cellar 